这是演示店铺,请务下单付款,避免造成你的财物损失。

为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

Ramucirumab (anti-VEGFR2)

功能和特点
  • 规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
  • 应用: ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
  • 反应种属: Cynomolgus,Human
  • 亚型: Human IgG1
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
R411995-1mg
1mg 期货 Stock Image
R411995-5mg
5mg 期货 Stock Image
R411995-10mg
10mg 期货 Stock Image

基本信息

产品名称 Ramucirumab (anti-VEGFR2)
别名 IMC-1121B, LY3009806, IMC-1121; CD309 antibody; CD309 antigen antibody; EC 2.7.10.1 antibody; Fetal liver kinase 1 antibody; FLK-1 antibody; FLK1 antibody; FLK1, mouse, homolog of antibody; Kdr antibody; Kinase insert domain receptor (a type III receptor
英文别名 IMC-1121B, LY3009806, IMC-1121; CD309 antibody; CD309 antigen antibody; EC 2.7.10.1 antibody; Fetal liver kinase 1 antibody; FLK-1 antibody; FLK1 antibody; FLK1, mouse, homolog of antibody; Kdr antibody; Kinase insert domain receptor (a type III receptor
规格或纯度 Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性 VEGFR2
应用 ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
反应种属 Cynomolgus,Human
偶联标记 Unconjugated

产品属性

抗体类型 Primary antibody
Format Whole IgG
亚型 Human IgG1
轻链亚型 Kappa
SDS-PAGE 26.5 kDa (Light Chain) & 50.5 kDa (Heavy Chain), under reducing conditions; 176.7 kDa, under non-reducing conditions
纯化方法 Protein A purified
来源 CHO supernatant
物理外观 Liquid
储存缓冲液 Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂 No
浓度 Lot by Lot
储存温度 -80℃储存,避免反复冻融
运输条件 超低温冰袋运输
稳定性与储存 Store at -80℃ long term (18 months). Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息 947687-13-0

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z.  (2002)  Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy..  Int J Cancer,  97  (3):  (393-9).  [PMID:11774295]
2. Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z.  (2003)  Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity..  J Biol Chem,  278  (44):  (43496-507).  [PMID:12917408]
3. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY et al..  (2019)  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial..  Lancet Oncol,  20  (2):  (282-296).  [PMID:30665869]

计算器